{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:18:30Z","timestamp":1791397110591,"version":"4.3.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001797","name":"PhRMA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jval.2021.10.016","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:32:04Z","timestamp":1638383524000},"page":"796-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otis W.","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeromie","family":"Ballreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2021.10.016_bib3","first-page":"9","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"168","author":"Huggins","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"10024","key":"10.1016\/j.jval.2021.10.016_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jval.2021.10.016_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.jval.2021.10.016_bib6","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2021.10.016_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2021.10.016_bib8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2021.10.016_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2021.10.016_bib11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jval.2021.10.016_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jval.2021.10.016_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A\u00a0cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"10.1016\/j.jval.2021.10.016_bib15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.urolonc.2019.05.017","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol Oncol"},{"issue":"Suppl:1","key":"10.1016\/j.jval.2021.10.016_bib16","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9 Suppl 1","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"issue":"11","key":"10.1016\/j.jval.2021.10.016_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.jval.2021.10.016_bib18","author":"Beth Woods"},{"issue":"10","key":"10.1016\/j.jval.2021.10.016_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine [published correction appears in JAMA. 2016;316(18):1924]","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jval.2021.10.016_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jval.2021.10.016_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jval.2015.08.012","article-title":"Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients","volume":"18","author":"Lloyd","year":"2015","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2021.10.016_bib28","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jval.2021.10.016_bib29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2021.10.016_bib31","series-title":"Network Meta-Analysis for Decision Making","author":"Dias","year":"2018"},{"issue":"4","key":"10.1016\/j.jval.2021.10.016_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"issue":"9","key":"10.1016\/j.jval.2021.10.016_bib34","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2021.10.016_bib35","first-page":"269","article-title":"Design, implementation, and first-year outcomes of a value-based drug formulary","volume":"21","author":"Sullivan","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.jval.2021.10.016_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MLR.0000000000000630","article-title":"Impact of a value-based formulary on medication utilization, health services utilization, and expenditures","volume":"55","author":"Yeung","year":"2017","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2021.10.016_bib37","unstructured":"Establishing minimum standards in Medicaid State drug utilization review (DUR) and supporting value-based purchasing (VBP) for drugs covered in Medicaid, revising Medicaid drug rebate and third party liability (TPL) requirements. U.S. Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/establishing-minimum-standards-medicaid-state-drug-utilization-review-dur-and-supporting-value-based-0. Accessed January 6, 2021."},{"issue":"6","key":"10.1016\/j.jval.2021.10.016_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.euo.2018.06.004","article-title":"Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness","volume":"1","author":"Woods","year":"2018","journal-title":"Eur Urol Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152103182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152103182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:27:29Z","timestamp":1761096449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152103182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S109830152103182X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.10.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}